2015
DOI: 10.1016/j.drudis.2014.11.004
|View full text |Cite
|
Sign up to set email alerts
|

The opportunities of mining historical and collective data in drug discovery

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
21
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 32 publications
(21 citation statements)
references
References 95 publications
0
21
0
Order By: Relevance
“…The current version of the CC is organized in 5 levels of complexity (A: Chemistry, B: Targets, C: Networks, D: Cells and E: Clinics), each of which is divided into 5 sublevels (1)(2)(3)(4)(5). In total, the CC is composed of 25 spaces capturing the 2D/3D structures of the molecules, targets and metabolic genes, network properties of the targets, cell response profiles, drug indications and side effects, among others ( Figure 1a).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…The current version of the CC is organized in 5 levels of complexity (A: Chemistry, B: Targets, C: Networks, D: Cells and E: Clinics), each of which is divided into 5 sublevels (1)(2)(3)(4)(5). In total, the CC is composed of 25 spaces capturing the 2D/3D structures of the molecules, targets and metabolic genes, network properties of the targets, cell response profiles, drug indications and side effects, among others ( Figure 1a).…”
Section: Resultsmentioning
confidence: 99%
“…The corpus of bioactivity records available suggests that other numerical representations of molecules are possible, reaching beyond chemical structures and capturing their known biological properties. Indeed, it has been shown that an enriched representation of molecules can be achieved through the use of 'bioactivity signatures' 3 . Bioactivity signatures are multi-dimensional vectors that capture the biological traits of the molecule (for example, its target profile) in a format that is akin to the structural descriptors or fingerprints used in the field of chemoinformatics.…”
Section: Introductionmentioning
confidence: 99%
“…[81] Recently, these approaches have been merged and further improved by simultaneously analyzing the behavior of compounds across multiple assays and clustering assays based on the compounds that they pick up. [82] Comparing the two axes of this compound-assay matrix seems a promising way to distinguish between common assay artifacts or general non-stoichiometric inhibitors affecting multiple related assays on the one hand and genuine polypharmacology based on stoichiometric inhibition on the other hand.…”
Section: In Silico Analysismentioning
confidence: 99%
“…Beyond the in-house bioactivity data collections generated and stored by pharmaceutical companies, several initiatives such as ChEMBL have made bioactivity data for millions of compounds publicly available (Gaulton et al, 2012). These range from interpretable classifiers such as inductive rules and decision trees (Drakakis, Moledina, Chomenidis, & Doganis, 2016) all the way to neural networks (Koutsoukas, Monaghan, Li, & Huan, 2017;Lenselink et al, 2017;Ma, Sheridan, Liaw, Dahl, & Svetnik, 2015;Ramsundar et al, 2015), random forests (Mervin et al, 2015), and support-vector machines (Wassermann, Lounkine, Davies, Glick, & Camargo, 2015). Target prediction refers to the algorithms used in cheminformatics to infer the mechanisms of action of small molecules by predicting their most likely protein targets from, e.g., their chemical structure (Koutsoukas et al, 2011) or by comparing the bioactivity profile of a test compound against those with known MoA across, e.g., a cancer cell line panel (Shoemaker, 2006).…”
Section: Target Predictionmentioning
confidence: 99%